drugset / Trial / NCT02417961

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

NCT02417961

Phase 3 Completed 162 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess functionality, performance, and reliability of an accessorized pre-filled syringe (APFS) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma.

Timeline

Start
2015-04-27
Primary completion
2016-03-14
Completion
2016-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody 30 mg Subcutaneous

Indications